enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Get breaking Business News and the latest corporate happenings from AOL. From analysts' forecasts to crude oil updates to everything impacting the stock market, it can all be found here.

  3. Japan's Otsuka Pharma to pay up to $1.1 billion to acquire ...

    www.aol.com/news/japans-otsuka-pharma-pay-1...

    TOKYO (Reuters) -Japan's Otsuka Pharmaceutical said on Thursday it agreed to pay more than $1 billion to acquire Jnana Therapeutics as it looks to expand its drug pipeline and research base in the ...

  4. Stock market news live updates: Tech leads stocks higher as ...

    www.aol.com/finance/stock-market-news-live...

    Click here for the latest stock market news and in-depth analysis, including events that move stocks Read the latest financial and business news from Yahoo Finance Download the Yahoo Finance app ...

  5. Astex Pharmaceuticals - Wikipedia

    en.wikipedia.org/wiki/Astex_Pharmaceuticals

    In 2011, Astex Therapeutics Limited and SuperGen, Inc. (US) merged. [10] Following the acquisition, SuperGen, Inc. changed its name to Astex Pharmaceuticals, Inc., and began trading under the ticker symbol ASTX on NASDAQ. [11] The combined Astex entities were subsequently acquired by Otsuka Pharmaceutical in October 2013 for around USD $900 ...

  6. Otsuka Pharmaceutical - Wikipedia

    en.wikipedia.org/wiki/Otsuka_Pharmaceutical

    Otsuka Pharmaceutical Co., Ltd. (大塚製薬株式会社, Ōtsuka Seiyaku Kabushiki-gaisha) (TYO: 4578), abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964.

  7. New Forecasts: Here's What Analysts Think The Future ... - AOL

    www.aol.com/news/forecasts-heres-analysts-think...

    For premium support please call: 800-290-4726 more ways to reach us

  8. AOL latest headlines, entertainment, sports, articles for business, health and world news.

  9. Why Summit Therapeutics Skyrocketed 123% This Week - AOL

    www.aol.com/why-summit-therapeutics-skyrocketed...

    Better-than-expected trial data means Summit's bispecific antibody could replace the blockbuster Keytruda as a standard of care for certain lung cancers.